CTIS2023-507039-39-00招募中1 期
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis - 77242113PSO3004
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 698
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1. =18 years of age at the screening visit., 2. Diagnosis of plaque psoriasis, with or without PsA, for at least 26 weeks prior to the first administration of study intervention., 3. Total BSA =10% at screening and baseline., 4. Total PASI =12 at screening and baseline., 5. Total IGA =3 at screening and baseline.
排除标准
- •1. Nonplaque form of psoriasis., 2. Current drug-induced psoriasis., 3. A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances., 4. Known allergies, hypersensitivity, or intolerance to JNJ-77242113, deucravacitinib, or to any of the excipients or components of the study intervention., 5. Major surgical procedure, within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study.
研究者
相似试验
进行中（未招募）
不适用
A Study of the Safety and Efficacy of Ustekinumab in Patients withPsoriatic Arthritis.MedDRA version: 14.1Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersPsoriatic ArthritisEUCTR2009-012264-14-FIJanssen-Cilag Internation N.V.600
进行中（未招募）
不适用
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled trial ofUstekinumab, a Fully Human anti-IL-12/23p40 Monoclonal Antibody,Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis Including Those Previously Treated with Biologic Anti-TNFa Agent(s) - PSUMMIT IIPsoriatric arthritisMedDRA version: 12.1Level: LLTClassification code 10037160Term: Psoriatic arthritisEUCTR2009-012265-60-ATJanssen Biologics B.V.300
进行中（未招募）
不适用
A Study of the Safety and Efficacy of Ustekinumab in Patients with Psoriatic ArthritisPsoriatic ArthritisEUCTR2009-012264-14-LTJanssen-Cilag International N.V.600
进行中（未招募）
不适用
A Study of the Safety and Efficacy of Ustekinumab in Patients with Psoriatic Arthritis with and without Prior Exposure to Anti-TNF AgentsMedDRA version: 14.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersPsoriatic arthritisEUCTR2009-012265-60-PLJanssen Biologics B.V.300
进行中（未招募）
不适用
This is a study of the safety and efficacy of ustekinumab (CNTO 1275) in adolescent patients with moderate to severe psoriasis.Moderate to Severe Plaque-type PsoriasisMedDRA version: 14.0Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2009-014368-20-HUJanssen Biologics B.V.150